Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lysosomal Storage Disorder Therapeutics Pipeline Analysis 2017: Approximately 74 Drug Candidates in Different Stages of Development - Research and Markets

Research and Markets
Posted on: 03 Aug 17

The "Lysosomal Storage Disorder Therapeutics Pipeline Analysis 2017" report has been added to Research and Markets' offering.

Lysosomal storage disorder refers to inherited metabolic disorders that are characterize by enzyme deficiencies, which results in an abnormal build-up of various toxic materials in the body's cells. There are nearly 50 types of lysosomal storage disorder which affect various parts of the body including the brain, skeleton, heart, central nervous system and skin.

The signs and symptoms vary for different diseases, according to the enzyme deficiency for this group of diseases. Some of the symptoms associated with lysosomal storage disorder include enlargement of the liver (hepatomegaly), rapidly progressive vision failure (optic atrophy), impaired kidney function, burning pain in the hands and feet, chronic fatigue, lethargy, mild mental retardation and abnormalities of the face and skull. Lysosomal storage disorder can be treated by bone marrow transplantation and enzyme replacement therapy (ERT). Some of the marketed drugs for lysosomal storage disorder include alglucerase injection (Ceredase), for treatment of Gaucher's disease type I; miglustat (Zavesca) for treatment of Gaucher's disease type I; Fabrazyme, for treatment of Fabry disease and Aldurazyme for treatment for Mucopolysaccharide Type I.

Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies with potential enzyme replacement therapies such as N-acetylglucosaminidase alpha (NAGLU) replacement which can also prove to be effective in Sanfilippo syndrome type B treatment. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.

As of June 2017, the lysosomal storage disorder therapeutics pipeline comprised of approximately 74 drug candidates in different stages of development.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Lysosomal Storage Disorder Therapeutics Pipeline Analysis By Phase (2017)

6. Competitive Landscape

7. Company Profiles

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/w22mt4/lysosomal_storage

View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005490/en/

Business Wire
www.businesswire.com

Last updated on: 03/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.